Management of Hematologic Disorders
Summary
- HIV-infected patients generally have adequate erythropoietic capacity; however, small amounts of epoetin alfa can increase hemoglobin and significantly reduce transfusion requirements of those with anemia[Fischl 1990; Henry 1992]
- Data from multiple studies evaluating increased hemoglobin target levels ≥ 13 g/dL using epoetin alfa have shown increased risk of cardiovascular events and death[Singh 2006; Drüeke 2006; Bohlius 2009]
- CMS recommendations for erythropoiesis-stimulating agent use when hemoglobin levels decrease to < 10 g/dL and not > 12 g/dL are reasonable for patients with HIV (Table 5)
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hematologic Complications